ORIC Pharmaceuticals, Inc.

113 articles about ORIC Pharmaceuticals, Inc.

• ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

  5/20/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results for the quarter ended March 31, 2020.

• ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  4/28/2020

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the closing of its initial public offering of 8,625,000 shares of its common stock,

• ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting

  4/27/2020

  Orally bioavailable small molecule CD73 inhibitors reverse immunosuppression by blocking adenosine production

• ORIC Pharmaceuticals Announces Pricing of Initial Public Offering

  4/23/2020

  ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of $16.00 per share.

• ORIC Pharmaceuticals Appoints Christian V. Kuhlen, M.D., as General Counsel

  4/2/2020

  ORIC Pharmaceuticals, Inc., a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Christian V. Kuhlen, M.D., has been named General Counsel

• 

  BioSpace Movers & Shakers, March 6

  3/6/2020

  Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.

• ORIC Pharmaceuticals Appoints Mardi C. Dier to its Board of Directors

  3/2/2020

  ORIC Pharmaceuticals, Inc., a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Mardi C. Dier to its board of directors.

• ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI® for the Treatment of Prostate Cancer in Collaboration with Astellas

  1/27/2020

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced dosing of the first patient in a Phase 1b clinical trial being conducted under a collaboration with Astellas Pharma Inc., to evaluate the combination of ORIC-101,

• ORIC Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/2/2020

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, MD, the Company's Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

• ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist at 2019 San Antonio Breast Cancer Symposium

  12/16/2019

  ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in triple-negative breast cancer

• ORIC Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

  12/2/2019

  ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance

• ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at AACR-NCI-EORTC Annual Conference

  10/28/2019

  Data on lead program demonstrated that glucocorticoids promote prostate tumor cell growth, stimulate androgen-regulated gene expression, and drive resistance to enzalutamide, effects that were completely reversed by ORIC-101

• ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer

  9/10/2019

  Mr. Piscitelli will serve on the executive leadership team and lead ORIC's finance, investor relations, and corporate operations functions.

• ORIC to Participate in Citi's 14th Annual Biotech Investor Conference

  8/28/2019

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced today that it will be participating in Citi's 14th Annual Biotech Conference in Boston.

• ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance

  8/8/2019

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing

• ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer

  7/9/2019

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced that Lori Friedman, PhD, has been named Chief Scientific Officer.

• ORIC Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

  5/28/2019

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance, announced that Jacob Chacko, MD, Chief Executive Officer, will present and host one-on-one investor meetings at the Jefferies 2019 Global Healthcare Conference held June 4-7th at the Grand Hyatt in New York.

• ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer

  5/13/2019

  Clinical study to evaluate the potential of ORIC’s novel glucocorticoid receptor antagonist to be used in combination with Abraxane®

• ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Mediated Cancer Treatment Resistance at the AACR Annual Meeting

  4/2/2019

  ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, today presented new preclinical data on its lead program ORIC-101, a selective and potent glucocorticoid receptor (GR) antagonist, at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA.

• ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical Development

  3/4/2019

  Dr. Chow Maneval will serve on the executive leadership team and, together with Chief Medical Officer Pratik Multani, MD, lead clinical development for ORIC.